Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical ...

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

In the assessment of 12-month price targets, analysts unveil insights for Lexicon Pharmaceuticals, presenting an average ...

HC Wainwright reiterated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research ...

Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 77.50%, which has investors questioning if this is right time ...

Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential ...

Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.

Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...

Similar to Yao Yao, gourmet and culinary researcher Zhong Yu'e told the Global Times that the food ingredients such as fish ...

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...